Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/1602
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorMARQUES, Herlander-
dc.contributor.authorCATARINO, Raquel-
dc.contributor.authorDOMINGUES, Nelson-
dc.contributor.authorBARROS, Eliane-
dc.contributor.authorPORTELA, Catarina-
dc.contributor.authorALMEIDA, Maria Ines-
dc.contributor.authorCOSTA, Sandra-
dc.contributor.authorREIS, Rui Manuel-
dc.contributor.authorMEDEIROS, Rui-
dc.contributor.authorLONGATTO-FILHO, Adhemar-
dc.date.accessioned2013-07-30T17:53:44Z-
dc.date.available2013-07-30T17:53:44Z-
dc.date.issued2012-
dc.identifier.citationONCOLOGY LETTERS, v.4, n.6, p.1285-1289, 2012-
dc.identifier.issn1792-1074-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1602-
dc.description.abstractThe Epstein-Barr virus (EBV) is associated with a large spectrum of lymphoproliferative diseases. Traditional methods of EBV detection include the immunohistochemical identification of viral proteins and DNA probes to the viral genome in tumoral tissue. The present study explored the detection of the EBV genome, using the BALF5 gene, in the bone marrow or blood mononuclear cells of patients with diffuse large B-cell lymphomas (DLBCL) and related its presence to the clinical variables and risk factors. The results show that EBV detection in 21.5% of patients is not associated with age, gender, staging, B symptoms, international prognostic index scores or any analytical parameters, including lactate dehydrogenase (LDH) or beta-2 microglobulin (B2M). The majority of patients were treated with R-CHOP-like (rituximab. cyclophosphamide, doxorubicin, vincristine and prednisolone or an equivalent combination) and some with CHOP-like chemotherapy. Response rates [complete response (CR) + partial response (PR)] were not significantly different between EBV-negative and -positive cases, with 93.2 and 88.9%, respectively. The survival rate was also similar in the two groups, with 5-year overall survival (OS) rates of 64.3 and 76.7%, respectively. However, when analyzing the treatment groups separately there was a trend in EBV-positive patients for a worse prognosis in patients treated with CHOP-like regimens that was not identified in patients treated with R-CHOP-like regimens. We conclude that EBV detection in the bone marrow and blood mononuclear cells of DLBC patients has the same frequency of EBV detection on tumoral lymphoma tissue but is not associated with the risk factors, response rate and survival in patients treated mainly with immunochemotherapy plus rituximab. These results also suggest that the addition of rituximab to chemotherapy improves the prognosis associated with EBV detection in DLBCL.-
dc.language.isoeng-
dc.publisherSPANDIDOS PUBL LTD-
dc.relation.ispartofOncology Letters-
dc.rightsopenAccess-
dc.subjectEpstein-barr virus-
dc.subjectnon-Hodgkin's lymphoma-
dc.subjectdiffuse large B-cell lymphoma-
dc.subjectmononuclear cells-
dc.subjectnon-Hodgkin's lymphoma risk factors-
dc.subject.otherlymphoproliferative disorder-
dc.subject.otherresistance-
dc.subject.otherinfection-
dc.subject.otherrituximab-
dc.subject.otherpcr-
dc.titleDetection of the Epstein-Barr virus in blood and bone marrow mononuclear cells of patients with aggressive B-cell non-Hodgkin's lymphoma is not associated with prognosis-
dc.typearticle-
dc.rights.holderCopyright SPANDIDOS PUBL LTD-
dc.identifier.doi10.3892/ol.2012.913-
dc.identifier.pmid23226803-
dc.subject.wosOncology-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.author.externalMARQUES, Herlander:Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal; Hosp Braga, Dept Oncol, Braga, Portugal-
hcfmusp.author.externalCATARINO, Raquel:Portuguese Inst Oncol, Mol Oncol Grp, Oporto, Portugal; Portuguese Inst Oncol, Virol Lab, Oporto, Portugal-
hcfmusp.author.externalDOMINGUES, Nelson:Inst Oncol, Dept Hematol Oncol, Oporto, Portugal-
hcfmusp.author.externalBARROS, Eliane:Portuguese Inst Oncol, Mol Oncol Grp, Oporto, Portugal; Portuguese Inst Oncol, Virol Lab, Oporto, Portugal-
hcfmusp.author.externalPORTELA, Catarina:Hosp Braga, Dept Oncol, Braga, Portugal-
hcfmusp.author.externalALMEIDA, Maria Ines:Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal-
hcfmusp.author.externalCOSTA, Sandra:Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal-
hcfmusp.author.externalREIS, Rui Manuel:Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal; Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, SP, Brazil-
hcfmusp.author.externalMEDEIROS, Rui:Portuguese Inst Oncol, Mol Oncol Grp, Oporto, Portugal; Pessoa Univ, Fac Hlth Sci Fernando, Oporto, Portugal; Portuguese Inst Oncol, Virol Lab, Oporto, Portugal-
hcfmusp.description.beginpage1285-
hcfmusp.description.endpage1289-
hcfmusp.description.issue6-
hcfmusp.description.volume4-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000311021500027-
hcfmusp.origem.id2-s2.0-84867240731-
hcfmusp.publisher.cityATHENS-
hcfmusp.publisher.countryGREECE-
hcfmusp.relation.referenceAMBINDER RF, 1994, AM J PATHOL, V145, P239-
hcfmusp.relation.referenceBanks PM, 2001, WHO CLASSIFICATION T, P189-
hcfmusp.relation.referenceCohen JI, 2000, NEW ENGL J MED, V343, P481, DOI 10.1056/NEJM200008173430707-
hcfmusp.relation.referenceDecker LL, 1996, J VIROL, V70, P3286-
hcfmusp.relation.referenceGibson SE, 2009, HUM PATHOL, V40, P653, DOI 10.1016/j.humpath.2008.10.007-
hcfmusp.relation.referenceHAMILTONDUTOIT SJ, 1993, BLOOD, V82, P619-
hcfmusp.relation.referenceHassan R, 2006, DIAGN PATHOL, V1, DOI 10.1186/1746-1596-1-17-
hcfmusp.relation.referenceHeid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986-
hcfmusp.relation.referenceHoeller S, 2010, HUM PATHOL, V41, P352, DOI 10.1016/j.humpath.2009.07.024-
hcfmusp.relation.referenceKelly G, 2002, NAT MED, V8, P1098, DOI 10.1038/nm758-
hcfmusp.relation.referenceKuzushima K, 2000, J INFECT DIS, V182, P937, DOI 10.1086/315791-
hcfmusp.relation.referenceMilpied N, 2000, ANN ONCOL, V11, P113, DOI 10.1023/A:1008372814223-
hcfmusp.relation.referenceMorales D, 2010, LEUKEMIA LYMPHOMA, V51, P66, DOI 10.3109/10428190903308015-
hcfmusp.relation.referenceMounier N, 2003, BLOOD, V101, P4279, DOI 10.1182/blood-2002-11-3442-
hcfmusp.relation.referenceOyama T, 2007, CLIN CANCER RES, V13, P5124, DOI 10.1158/1078-0432.CCR-06-2823-
hcfmusp.relation.referencePark S, 2007, BLOOD, V110, P972, DOI 10.1182/blood-2007-01-067769-
hcfmusp.relation.referencePaydas S, 2009, LEUKEMIA RES, V33, P4117-
hcfmusp.relation.referenceSwerdlow SH, 2008, WHO CLASSIFICATION T-
hcfmusp.relation.referenceThorley-Lawson DA, 2004, NEW ENGL J MED, V350, P1328, DOI 10.1056/NEJMra032015-
hcfmusp.relation.referenceTIERNEY RJ, 1994, J VIROL, V68, P7374-
hcfmusp.relation.referenceYoshino T, 2006, CANCER SCI, V97, P163, DOI 10.1111/j.1349-7006.2006.00155.x-
dc.description.indexPubMed-
hcfmusp.lim.ref2012-
hcfmusp.citation.scopus5-
hcfmusp.scopus.lastupdate2022-05-06-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - LIM/14
LIM/14 - Laboratório de Investigação em Patologia Hepática


Files in This Item:
File Description SizeFormat 
art_LONGATTO-FILHO_Detection_of_the_Epstein_Barr_virus_in_blood_2012.PDFpublishedVersion (English)307.52 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.